Vascular Interventions DABRA's FDA clearance for crossing chronic total occlusions in infrainguinal PAD positions Ra Medical as a focused solution for vascular interventions. Sales opportunities exist with hospital vascular surgery and interventional radiology teams through device adoption discussions, training, and bundled catheter supply programs emphasizing minimally invasive laser-assisted recanalization and patient outcomes.

Channel Expansion The 2022 merger with Catheter Precision and 2023 LockeT launches strengthen Ra Medical's catheter-based portfolio and sales channels. This creates a pathway to expand distribution in cardiology and electrophysiology labs, cross-sell DABRA and LockeT products, and partner with hospitals seeking integrated catheter-based solutions.

Manufacturing Advantage A vertically integrated, ISO 13485 certified Carlsbad facility licensed to manufacture sterile single-use catheters enables reliable, compliant national supply. This supports hospital procurement needs and opens opportunities for private-label or contract manufacturing partnerships with vascular-focused manufacturers or distributors.

Leadership Signals Recent leadership changes, including a new CEO, new CFO, and an Executive Chairman, indicate a strategic push toward growth, potential fundraising, and expanded patient-care partnerships in vascular markets. Engage with executive leadership to discuss strategic collaborations, capital needs, and long-term supplier relationships.

Market Adoption With ongoing product development such as LockeT and a pivot to vascular applications, Ra Medical can target healthcare systems expanding PAD programs and endovascular suites. Focus on procurement cycles, clinical adoption opportunities, and payer considerations to drive recurring device demand for DABRA lasers and associated catheters.